Lifeline offered to melanoma patients out of options
NCT ID NCT04489433
Summary
This program provided access to two targeted drugs, trametinib and dabrafenib, for adults with advanced, BRAF mutation-positive melanoma who had no other treatment options available. It was a compassionate use program, meaning it offered the drugs outside of regular clinical trials to patients in urgent need. The program continued until the drugs became commercially available or other treatments were found.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.